Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus

• Published in: Diabetes research and clinical practice 2005-08, Vol.69 (2), p.196-204
• Main Authors: Oli, J.M., Adeyemo, A.A., Okafor, G.O., Ofoegbu, E.N., Onyenekwe, B., Chukwuka, C.J., Chen, G., Chen, Y., Doumatey, A.P., Aje, T.O., Rotimi, C.N.
• Format: Article
• Language: English
• Subjects: Beta-cell function; Blood Glucose - metabolism; Body Mass Index; Body Size; C-peptide; C-Peptide - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Fasting; Female; Humans; Islets of Langerhans - secretion; Male; Middle Aged; Nigeria; Nigerians; Type 2 Diabetes mellitus
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2004.12.006

There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital. After 9 months of follow-up and treatment, they were categorized into three groups based on response to treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) inadequate control but not on maximum SU therapy and (C) on maximum SU therapy ± insulin or biguanide. Logistic regression models were used to investigate how well C-peptide levels predicted the subjects belonging to Group C who are likely to require insulin. The mean FCP and mean GSCP levels of Group C were significantly lower than in the other groups ( p = 0.024; p =